Illumina unveils plans to cut costs as it faces shrinking margins

Illumina unveils plans to cut costs as it faces shrinking margins


A building on the campus at the world headquarters of Illumina is shown in San Diego, California, September 1, 2021.

Mike Blake | Reuters

Illumina on Tuesday unveiled plans to cut costs in a bid to improve the DNA sequencing company’s shrinking margins.

The plans aim to reduce Illumina’s annualized run rate expenses by more than $100 million starting later this year, according to the company’s first quarter earnings release.

related investing news

Wells Fargo upgrades this medical device maker, cites improving industry trends

CNBC Pro

The company reported gross margins of 60.3% for the period, down from 66.6% during the same period a year before.

“These cost savings will accelerate progress toward higher margins as well as free up capital to increase investment in high-growth areas,” Illumina said in the release.

The company is also battling criticism and a falling market cap in the wake of its controversial acquisition of Grail, a cancer screening company.

The San Diego-based company’s market value has fallen to roughly $34.5 billion from around $75 billion in August 2021, the month it closed its acquisition of cancer test developer Grail. 

Antitrust regulators have repeatedly pushed back on the $7.1 billion Grail deal. 

The U.S. Federal Trade Commission earlier this month ordered Illumina to divest the acquisition, saying it would stifle competition and innovation. 

The EU’s executive body, the European Commission, last year blocked the deal over similar concerns.  

Illumina said it is appealing both orders and expects a final decision in late 2023 or early 2024. 

The Grail deal is also the focus of a proxy fight between activist investor Carl Icahn and Illumina, who have been trading jabs for more than a month.

Icahn, who owns a 1.4% stake in Illumina, is seeking seats on Illumina’s board of directors and pushing the company to unwind the deal. He is also calling for Illumina to oust its CEO Francis deSouza “immediately.” 

The company is urging shareholders to reject Icahn’s three board nominees during the company’s annual shareholder meeting on May 25. 

Illumina has repeatedly claimed that Grail has “tremendous long-term value creation potential.” 

Grail claims to offer the only commercially available early screening test that can detect more than 50 types of cancers through a single blood draw. 

The cancer test generated around $55 million in revenue in 2022 and is expected to rake in up to $110 million this year, Illumina said last month.



Source

Healthy Returns: AstraZeneca CEO proposes some U.S. drug price cuts amid Trump pressure
Health

Healthy Returns: AstraZeneca CEO proposes some U.S. drug price cuts amid Trump pressure

The office building of international biopharmaceutical company AstraZeneca. Cfoto | Future Publishing | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. President Donald Trump has been pressuring pharmaceutical companies to lower U.S. drug […]

Read More
Trump’s pharmaceutical tariffs could affect some drugmakers more than others
Health

Trump’s pharmaceutical tariffs could affect some drugmakers more than others

Medications are stored on shelves at a pharmacy on May 12, 2025 in Los Angeles, California. Eric Thayer | Getty Images President Donald Trump is slated to impose tariffs on pharmaceuticals imported into the U.S. any day now – and the duties may have a bigger impact on some drugmakers than others, according to some […]

Read More
Merck plans  billion cost cuts by end of 2027, narrows full-year outlook
Health

Merck plans $3 billion cost cuts by end of 2027, narrows full-year outlook

Merck & Co. signage on the floor of the New York Stock Exchange (NYSE) in New York, US, on Tuesday, April 8, 2025. Michael Nagle | Bloomberg | Getty Images Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches […]

Read More